Some examples of these include termination of a basket trial for anti-CTLA-4 and PD-L1 combination therapy assessment in metastatic solid tumors (NCT03982173) and anti-CTLA-4 in advanced melanoma (NCT 01740401) due to non-encouraging results. This evidence concerns the gene CD274 and melanoma.